Clinical Trial Search

Primary: Percentage of Subjects With a ≥1 Grade Improvement From Baseline in Infra-Orbital Area on the Allergan Infra-Orbital Rating Scale (AIRS) on the Right and Left Side — 99…

Primary: Volumetric Change in Infraorbital Treatment Baseline to Each Post-intervention Timepoint Day 14, Day 30, and Day 90 — -0.026; -0.065; -0.108 cc

Primary: Responder Rate Compared to the Untreated Control Group According to the Merz Infraorbital Hollow Assessment Scale (MIHAS). — 81.6; 9.5 percentage of participants — p=<…

Primary: Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Infraorbital Hollows Scale (GIHS) — 87.4; 17.7 Percentage of participants — p=<0.001

Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…

Primary: Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment, Using the TIOHS - Phase 1a…

Primary: Responder Rate Based on Merz Infraorbital Hollow Assessment Scale (MIHAS) at Week 8 — 80.6; 87.4; 73.7; 1.9 percentage of subjects

Primary: Graded Change in Dermatochalasis — .2679 units on a scale

Primary: Nasal Tip Projection — 0.601 ratio

Primary: Percentage of Participants by Improvement Rating (Improved and Not Improved) of Their Dynamic Radial Cheek Lines as Assessed by the Participant Using the Global…

Primary: Percentage of Participants With at Least a 1-point Improvement Change From Baseline on the Allergan Infraorbital Hollows Scale (AIHS) Based on Evaluating Investigator's…

Primary: Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention — 0; 0 participants — p==1

Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…

Primary: Percentage of Participants With Safety Adverse Events — 3.92 Percentage of Participants

Primary: First Impressions — 46.756; 27.769; 46.391; 34.404 score on a scale

Primary: Micropore Depth, Upper Arm — 72.4 micrometer

Primary: Change From Baseline in Texture Score at Visit 4 (End-of-study Session) — 0.25; -4.75 score on a scale — p=0.075

Primary: Percentage of Participants With Lower Scar Severity in the Treated Cheek Compared to the Untreated Cheek — 81 percentage of participants

Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score

Primary: Change in Lower Eyelid Bags. — 5; 5 Participants

Primary: Responder Rate in Reduction of Nasolabial Folds — 34; 39; 73 Participants

Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants

Primary: Pain Score Using a 10-cm Visual Analog Scale (VAS) for Pain (0 = no Pain, 10 = Very Severe Pain) — 2.32; 6.73 units on a scale — p=<0.0001

Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds

Primary: Blinded Evaluations of First Impression — 7.35 score on a scale

Primary: Keloid Formation at Site of Injection — 0.0 percentage of participants

Primary: Percentage of Participants With 1 Point Improvement From Baseline on the Medicis Midface Volume Scale (MMVS) as Measured by the Blinded Evaluator at Month 12 — 68.8…

Primary: Proportion of Participants With Improvement in Periorbital Wrinkles From Baseline — 10; 2; 8; 2 Participants

Primary: Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale — 67; 8 Participants

Primary: Number of Participants With Adverse Events — 23; 59; 1; 2 Participants